Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug News Perspect. 2007 Nov;20(9):565-71. doi: 10.1358/dnp.2007.20.9.1162244.

5-HT2C receptor agonists as an innovative approach for psychiatric disorders.

Author information

1
Wyeth Discovery Neuroscience, Princeton, New Jersey 08543, USA. rosenzs@wyeth.com

Abstract

Modulating activity at the 5-HT(2C) receptor holds a tremendous amount of therapeutic promise in multiple psychiatric indications. However, the signaling and regulation of the 5-HT(2C) receptor is highly complex due to multiple signaling pathways and agonist-directed trafficking of this receptor. Moreover, the 5-HT(2C) receptor is differentially regulated via RNA editing in multiple psychiatric disorders and following either pharmacological or environmental manipulation. Direct and indirect data suggest that both agonists and antagonists may provide benefits in several disorders. The current review highlights the underlying complexities of this area and provides the rationale for using 5-HT(2C) agonists in the treatment of both schizophrenia and depressive disorders.

PMID:
18176661
DOI:
10.1358/dnp.2007.20.9.1162244
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Clarivate Analytics
    Loading ...
    Support Center